{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:23:47Z","timestamp":1792783427159,"version":"4.5.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"The University of Queensland","id":[{"id":"https:\/\/ror.org\/00rqy9422","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Med"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40290-026-00627-9","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:20:33Z","timestamp":1786645233000},"page":"441-455","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Application of Actor Network Theory to Evaluate Supply and Demand Strategies Used to Encourage International Biosimilar Uptake"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1902-0343","authenticated-orcid":false,"given":"Chad","family":"Rieger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7715-6391","authenticated-orcid":false,"given":"Judith A.","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9931-7830","authenticated-orcid":false,"given":"Gregory","family":"Merlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9309-9315","authenticated-orcid":false,"given":"Lisa","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"627_CR1","unstructured":"European Medicines Agency. Biosimilar medicines: Overview. 2025 [cited 2025 18 October]; Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/biosimilar-medicines-overview."},{"key":"627_CR2","unstructured":"Australian Government. Trans-pacific partnership agreement - outcomes: Biologics. 2016 [cited 1 Aug 2025]; Available from: https:\/\/www.dfat.gov.au\/sites\/default\/files\/outcomes-biologics.pdf."},{"key":"627_CR3","unstructured":"IQVIA. The impact of biosimilar competition in Europe. 2021 [cited 5 November 2025]; Available from: https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/library\/white-papers\/the-impact-of-biosimilar-competition-in-europe-2021.pdf."},{"issue":"5","key":"627_CR4","doi-asserted-by":"publisher","first-page":"e034183","DOI":"10.1136\/bmjopen-2019-034183","volume":"10","author":"K Sarnola","year":"2020","unstructured":"Sarnola K, Merikoski M, Jyrkk\u00e4 J, H\u00e4meen-Anttila K. Physicians\u2019 perceptions of the uptake of biosimilars: a systematic review. BMJ Open. 2020;10(5):e034183\u2013e034183. https:\/\/doi.org\/10.1136\/bmjopen-2019-034183.","journal-title":"BMJ Open"},{"key":"627_CR5","unstructured":"Organisation for Economic Cooperation and Development (OECD). Health at a Glance 2023: OECD Indicators. Generics and Biosimilars 2023 [cited 18 Feb 2026]; Available from:https:\/\/www.oecd.org\/en\/publications\/health-at-a-glance-2023_7a7afb35-en.html."},{"key":"627_CR6","unstructured":"Pharmaceutical Benefits Scheme (PBS). PBS expenditure and prescriptions report 1 July 2024 to 30 June 2025. [cited 1 Feb 2026]; Available from: https:\/\/www.pbs.gov.au\/info\/statistics\/expenditure-prescriptions\/expenditure-prescriptions-report-1-july-2024-30-june-2025."},{"key":"627_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1188368","volume":"14","author":"KA Alnaqbi","year":"2023","unstructured":"Alnaqbi KA, Bellanger A, Brill A, Casta\u00f1eda-Hern\u00e1ndez G, Clop\u00e9s Estela A, Delgado S\u00e1nchez O, et al. An international comparative analysis and roadmap to sustainable biosimilar markets. Front Pharmacol. 2023;14:1188368. https:\/\/doi.org\/10.3389\/fphar.2023.1188368.","journal-title":"Front Pharmacol"},{"key":"627_CR8","doi-asserted-by":"publisher","unstructured":"Vogler S, Schneider P, Zuba M, Busse R, Panteli D. Policies to encourage the use of biosimilars in European countries and their potential impact on pharmaceutical expenditure. Front Pharmacol; 2021:12. https:\/\/doi.org\/10.3389\/fphar.2021.625296. https:\/\/www.frontiersin.org\/article\/.","DOI":"10.3389\/fphar.2021.625296"},{"issue":"3","key":"627_CR9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40259-019-00345-6","volume":"33","author":"E Moorkens","year":"2019","unstructured":"Moorkens E, Simoens S, Troein P, Declerck P, Vulto AG, Huys I. Different policy measures and practices between Swedish counties influence market dynamics: part 1\u2014biosimilar and originator infliximab in the hospital setting. BioDrugs. 2019;33(3):285\u201397. https:\/\/doi.org\/10.1007\/s40259-019-00345-6.","journal-title":"BioDrugs"},{"issue":"288","key":"627_CR10","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.3389\/fphar.2017.00288","volume":"8","author":"P Kawalec","year":"2017","unstructured":"Kawalec P, Stawowczyk E, Tesar T, Skoupa J, Turcu-Stiolica A, Dimitrova M. Pricing and reimbursement of biosimilars in central and Eastern European countries. Front Pharmacol. 2017;8(288):2017. https:\/\/doi.org\/10.3389\/fphar.2017.00288.","journal-title":"Front Pharmacol."},{"issue":"1","key":"627_CR11","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2017.1307315","volume":"5","author":"C R\u00e9muzat","year":"2017","unstructured":"R\u00e9muzat C, Kapu\u015bniak A, Caban A, Ionescu D, Radi\u00e8re G, Mendoza C, et al. Supply-side and demand-side policies for biosimilars: an overview in 10 European member states. J Mark Access Health Policy. 2017;5(1):1307315. https:\/\/doi.org\/10.1080\/20016689.2017.1307315.","journal-title":"J Mark Access Health Policy"},{"issue":"1","key":"627_CR12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1586\/14737167.2015.1067142","volume":"16","author":"V Brodszky","year":"2016","unstructured":"Brodszky V, Rencz F, P\u00e9ntek M, Baji P, Lakatos PL, Gul\u00e1csi L. A budget impact model for biosimilar infliximab in Crohn\u2019s disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia. Expert Rev Pharmacoecon Outcomes Res. 2016;16(1):119\u201325. https:\/\/doi.org\/10.1586\/14737167.2015.1067142.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"2","key":"627_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002560","volume":"8","author":"H Nabi","year":"2022","unstructured":"Nabi H, Hendricks O, Jensen DV, Loft AG, Pedersen JK, Just SA, et al. Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry. RMD Open. 2022;8(2):e002560. https:\/\/doi.org\/10.1136\/rmdopen-2022-002560.","journal-title":"RMD Open"},{"issue":"1","key":"627_CR14","doi-asserted-by":"publisher","first-page":"1705120","DOI":"10.2147\/CEOR.S140063","volume":"8","author":"S Simoens","year":"2020","unstructured":"Simoens S, Cheung R. Tendering and biosimilars: what role for value-added services? J Market Access Health Policy. 2020;8(1):1705120. https:\/\/doi.org\/10.2147\/CEOR.S140063.","journal-title":"J Market Access Health Policy"},{"key":"627_CR15","unstructured":"Wilsdon T, Pistollato M, Ross-Stewart K, Saada R, Barquin P, Alnaqbi KA, et al. Biosimilars: a global roadmap for policy sustainability. Charles River Associates; 2022."},{"issue":"5","key":"627_CR16","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s40258-023-00812-w","volume":"21","author":"M Tano","year":"2023","unstructured":"Tano M, Paubel P, Ribault M, Degrassat-Th\u00e9as A. What about offering a financial incentive directly to clinical units to encourage the use of biosimilars? Results of a two-year national experiment in France. Appl Health Econ Health Policy. 2023;21(5):799\u2013811. https:\/\/doi.org\/10.1007\/s40258-023-00812-w.","journal-title":"Appl Health Econ Health Policy"},{"key":"627_CR17","doi-asserted-by":"crossref","unstructured":"Shin G, Han H, Choi G, Lee D, Bae S. Demand-versus supply-side policies in market penetration of biosimilars: which is more effective? BioDrugs. 2025;1\u201310.","DOI":"10.1007\/s40259-025-00721-5"},{"key":"627_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/oso\/9780199256044.001.0001","volume-title":"Reassembling the social: an introduction to actor-network-theory","author":"B Latour","year":"2005","unstructured":"Latour B. Reassembling the social: an introduction to actor-network-theory. Oxford: Oxford University Press, Incorporated; 2005."},{"key":"627_CR19","unstructured":"Mayes R, Hurst B, Hine A. ANT stakeholder action mapping tool and user guide; 2021."},{"issue":"2","key":"627_CR20","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1108\/JHOM-12-2019-0339","volume":"34","author":"A Altabaibeh","year":"2020","unstructured":"Altabaibeh A, Caldwell KA, Volante MA. Tracing healthcare organisation integration in the UK using actor\u2013network theory. J Health Organ Manag. 2020;34(2):192\u2013206.","journal-title":"J Health Organ Manag"},{"key":"627_CR21","doi-asserted-by":"crossref","unstructured":"McLachlan AJ, Aslani P. National medicines Policy 2.0: a vision for the future. Aust Prescriber. 2020;43(1): 24.","DOI":"10.18773\/austprescr.2020.007"},{"issue":"1","key":"627_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2023-014425","volume":"9","author":"R Ravinetto","year":"2024","unstructured":"Ravinetto R, Henriquez R, Srinivas PN, Bradley H, Coetzee R, Ochoa TJ, et al. Shaping the future of global access to safe, effective, appropriate and quality health products. BMJ Glob Health. 2024;9(1):e014425.","journal-title":"BMJ Glob Health"},{"issue":"4","key":"627_CR23","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.annals.2009.06.001","volume":"36","author":"K Rodger","year":"2009","unstructured":"Rodger K, Moore SA, Newsome D. Wildlife tourism, science and actor network theory. Ann Tour Res. 2009;36(4):645\u201366. https:\/\/doi.org\/10.1016\/j.annals.2009.06.001.","journal-title":"Ann Tour Res"},{"issue":"3","key":"627_CR24","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1111\/j.1467-8330.2011.00926.x","volume":"44","author":"LS Horowitz","year":"2012","unstructured":"Horowitz LS. Translation alignment: actor-network theory, resistance, and the power dynamics of alliance in New Caledonia. Antipode. 2012;44(3):806\u201327.","journal-title":"Antipode"},{"key":"627_CR25","unstructured":"Pharmaceutical Benefits Scheme (PBS). About: detailed information on how prescription medicines are priced under the PBS and RPBS for pharmacists. [cited 5 March 2026]; Available from: https:\/\/www.servicesaustralia.gov.au\/about-pbs-for-pharmacists?context=22861."},{"key":"627_CR26","doi-asserted-by":"crossref","unstructured":"Barrenho E, Kim D, Moens M, Waagstein L. Assessing the impact of promotion and advertising regulations on biosimilar uptake. OECD Health Working Papers; 2025.","DOI":"10.1787\/c69f54b2-en"},{"key":"627_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.821616","author":"L Barbier","year":"2022","unstructured":"Barbier L, Simoens S, Declerck P, Vulto AG, Huys I. Biosimilar use and switching in Belgium: avenues for integrated policymaking. Front Pharmacol. 2022. https:\/\/doi.org\/10.3389\/fphar.2022.821616.","journal-title":"Front Pharmacol"},{"key":"627_CR28","unstructured":"Baig M. Biosimilar switching in Germany from March 15, 2024. 2024. [cited 15 Mar 2026]; Available from: https:\/\/remapconsulting.com\/biosimilars\/biosimilar-switching-in-germany-from-march-15-2024\/#:~:text=Substitution%20is%20permissible%20between%20a,pricing%20strategies%20for%20their%20products."},{"key":"627_CR29","doi-asserted-by":"publisher","unstructured":"Tam AC, Badesha J, Guh DP, Bansback N, Peter KK, Hollis A, et al. Biosimilar policies and their impact on market penetration of adalimumab, etanercept and infliximab: a policy synthesis and descriptive analysis in 13 OECD countries. BioDrugs. 2025;1\u201316. https:\/\/doi.org\/10.1007\/s40259-025-00709-1.","DOI":"10.1007\/s40259-025-00709-1"},{"key":"627_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2024.1263472","volume":"12","author":"S Machado","year":"2024","unstructured":"Machado S, Cruz A, Ferreira PL, Morais C, Pimenta RE. Policy measures and instruments used in European countries to increase biosimilar uptake: a systematic review. Front Public Health. 2024;12:1263472. https:\/\/doi.org\/10.3389\/fpubh.2024.1263472.","journal-title":"Front Public Health"},{"issue":"10","key":"627_CR31","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1007\/s00228-021-03155-4","volume":"77","author":"S Azuz","year":"2021","unstructured":"Azuz S, Newton M, Bartels D, Poulsen BK. Uptake of biosimilar trastuzumab in Denmark compared with other European countries: a comparative study and discussion of factors influencing implementation and uptake of biosimilars. Eur J Clin Pharmacol. 2021;77(10):1495\u2013501. https:\/\/doi.org\/10.1007\/s00228-021-03155-4.","journal-title":"Eur J Clin Pharmacol"},{"key":"627_CR32","unstructured":"NHS England. Commissioning framework for best value biological medicines. 2025. [cited 1 June 2026]; Available from: https:\/\/www.england.nhs.uk\/long-read\/commissioning-framework-for-best-value-biological-medicines\/."},{"issue":"3","key":"627_CR33","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40259-019-00346-5","volume":"33","author":"E Moorkens","year":"2019","unstructured":"Moorkens E, Simoens S, Troein P, Declerck P, Vulto AG, Huys I. Different policy measures and practices between Swedish counties influence market dynamics: part 2\u2014biosimilar and originator etanercept in the outpatient setting. BioDrugs. 2019;33(3):299\u2013306. https:\/\/doi.org\/10.1007\/s40259-019-00346-5.","journal-title":"BioDrugs"},{"issue":"12","key":"627_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190147","volume":"12","author":"E Moorkens","year":"2017","unstructured":"Moorkens E, Vulto AG, Huys I, Dylst P, Godman B, Keuerleber S, et al. Policies for biosimilar uptake in Europe: an overview. PLoS One. 2017;12(12):e0190147. https:\/\/doi.org\/10.1371\/journal.pone.0190147.","journal-title":"PLoS One"},{"key":"627_CR35","doi-asserted-by":"publisher","unstructured":"McClean A. Evaluating biosimilars uptake and policy in Canada. 2022, University of British Columbia. https:\/\/doi.org\/10.14288\/1.0421384.","DOI":"10.14288\/1.0421384"},{"key":"627_CR36","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1136\/annrheumdis-2024-eular.1527","volume":"83","author":"K Shastri","year":"2024","unstructured":"Shastri K, Clarke K, Ainslie-Garcia M, Ferko N. AB1428 Adalimumab and tocilizumab biosimilars in Europe: budget-impact and opportunity for expanded patient access. Ann Rheum Dis. 2024;83:2069\u201370.","journal-title":"Ann Rheum Dis"},{"key":"627_CR37","unstructured":"Zhang Y. Canada\u2019s evolving market for biosimilars and what it means for payers. Government of Canada; 2025. [cited 1 June 2026]; Available from: https:\/\/www.canada.ca\/en\/patented-medicine-prices-review\/services\/npduis\/analytical-studies\/posters\/biosimilars-2025poster.html."},{"key":"627_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1151764","volume":"14","author":"E Car","year":"2023","unstructured":"Car E, Vulto AG, Houdenhoven MV, Huys I, Simoens S. Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends. Front Pharmacol. 2023;14:1151764.","journal-title":"Front Pharmacol"},{"issue":"12","key":"627_CR39","doi-asserted-by":"publisher","first-page":"S272","DOI":"10.1016\/j.jval.2023.09.1422","volume":"26","author":"K Schmidt","year":"2023","unstructured":"Schmidt K, Konstanski M, Martinez JS, Watts-James J. HPR104 A review of biosimilar utilization across EU4 and UK since the introduction of the first biosimilar. Value Health. 2023;26(12):S272.","journal-title":"Value Health"},{"key":"627_CR40","unstructured":"Biosimilars uptake rates in Europe and the UK, in Generics and Biosimilars Initiative. 2023; [cited 7 June 2026]; Available from: https:\/\/gabionline.net\/reports\/biosimilars-uptake-rates-in-europe-and-the-uk."},{"key":"627_CR41","unstructured":"Pharmaceutical Benefits Scheme (PBS). Pharmaceutical Benefits. Fees, patient contributions, and safety net thresholds 2024 [cited 15 May 2026]. Available from: https:\/\/www.pbs.gov.au\/info\/healthpro\/explanatory-notes\/front\/fee."},{"key":"627_CR42","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-349-07408-2","volume-title":"Mapping the dynamics of science and technology: sociology of science in the real world","author":"M Callon","year":"1986","unstructured":"Callon M, Rip A, Law J. Mapping the dynamics of science and technology: sociology of science in the real world. Springer; 1986."},{"issue":"1_suppl","key":"627_CR43","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/j.1467-954X.1984.tb00113.x","volume":"32","author":"M Callon","year":"1984","unstructured":"Callon M. Some elements of a sociology of translation: domestication of the scallops and the fishermen of St Brieuc Bay. Sociol Rev. 1984;32(1_suppl):196\u2013233.","journal-title":"Sociol Rev"},{"key":"627_CR44","doi-asserted-by":"publisher","unstructured":"Nabi H, Ibsen R, Ibsen M, Kjellberg J, Hetland ML, Glintborg B. Counting the costs: a nationwide study on healthcare use following an adalimumab biosimilar switch in> 1300 inflammatory arthritis patients. Therap Adv Musculoskeletal Dis. 2024;16: 1759720X241289391. https:\/\/doi.org\/10.1177\/1759720X241.","DOI":"10.1177\/1759720X241"},{"issue":"2","key":"627_CR45","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s40259-022-00523-z","volume":"36","author":"T Barcina Lacosta","year":"2022","unstructured":"Barcina Lacosta T, Vulto AG, Turcu-Stiolica A, Huys I, Simoens S. Qualitative analysis of the design and implementation of benefit-sharing programs for biologics across Europe. BioDrugs. 2022;36(2):217\u201329. https:\/\/doi.org\/10.1007\/s40259-022-00523-z.","journal-title":"BioDrugs"},{"key":"627_CR46","unstructured":"Pharmaceutical Benefits Scheme (PBS). Biosimilar uptake drivers. 2017 [cited 15 June 2025]; Available from: https:\/\/www.pbs.gov.au\/general\/biosimilars\/biosimilar-uptake-drivers-q-and-a.pdf."},{"issue":"1","key":"627_CR47","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2016.1272308","volume":"5","author":"C R\u00e9muzat","year":"2017","unstructured":"R\u00e9muzat C, Dorey J, Cristeau O, Ionescu D, Radi\u00e8re G, Toumi M. Key drivers for market penetration of biosimilars in Europe. J Mark Access Health Policy. 2017;5(1):1272308. https:\/\/doi.org\/10.1080\/20016689.2016.1272308.","journal-title":"J Mark Access Health Policy"},{"issue":"1","key":"627_CR48","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00228-019-02765-3","volume":"76","author":"TB Jensen","year":"2020","unstructured":"Jensen TB, Bartels D, S\u00e6dder EA, Poulsen BK, Andersen SE, Christensen MMH, et al. The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars. Eur J Clin Pharmacol. 2020;76(1):35\u201340. https:\/\/doi.org\/10.1007\/s00228-019-02765-3.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"627_CR49","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/ajd.14427","volume":"66","author":"GX Li","year":"2025","unstructured":"Li GX, Marabani M, Sebaratnam DF. Biosimilars for Australian dermatologists. Australas J Dermatol. 2025;66(3):152\u20136. https:\/\/doi.org\/10.1111\/ajd.14427.","journal-title":"Australas J Dermatol"},{"key":"627_CR50","unstructured":"Pharmaceutical Benefits Scheme (PBS). PBS expenditure and prescriptions report 1 July 2023 to 30 June 2024. [cited 1 June 2026]; Available from: https:\/\/www.pbs.gov.au\/info\/statistics\/expenditure-prescriptions\/expenditure-prescriptions-report-1-july-2023-30-june-2024#:~:text=Expenditure%20and%20Prescription%20Snapshot%20%2D%202023,8.4%25%20of%20total%20medicine%20cost."},{"issue":"10","key":"627_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/ph13100324","volume":"13","author":"E Moorkens","year":"2020","unstructured":"Moorkens E, Barcina Lacosta T, Vulto AG, Schulz M, Gradl G, Enners S, et al. Learnings from regional market dynamics of originator and biosimilar infliximab and etanercept in Germany. Pharmaceuticals (Basel). 2020;13(10):324. https:\/\/doi.org\/10.3390\/ph13100324.","journal-title":"Pharmaceuticals (Basel)"},{"key":"627_CR52","doi-asserted-by":"crossref","unstructured":"Curto A, Van de Vooren K, Garattini L, Lo Muto R, Duranti S. Regional tenders on biosimilars in Italy: potentially competitive. Gen Biosimil J. 2013; 2(3): 123\u2013129.","DOI":"10.5639\/gabij.2013.0203.036"},{"issue":"3","key":"627_CR53","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jsis.2013.03.002","volume":"22","author":"K Dery","year":"2013","unstructured":"Dery K, Hall R, Wailes N, Wiblen S. Lost in translation? An actor-network approach to HRIS implementation. J Strateg Inf Syst. 2013;22(3):225\u201337. https:\/\/doi.org\/10.1016\/j.jsis.2013.03.002.","journal-title":"J Strateg Inf Syst"},{"key":"627_CR54","volume-title":"Traducci\u00f3n y sostenibilidad cultural [Recurso electr\u00f3nico]: sustrato, fundamentos y aplicaciones","author":"G Silva","year":"2019","unstructured":"Silva G. Traduttore-traditore all over again?: The concept of translation in the actor-network theory. In: Traducci\u00f3n y sostenibilidad cultural [Recurso electr\u00f3nico]: sustrato, fundamentos y aplicaciones. Ediciones Universidad de Salamanca; 2019."},{"issue":"3","key":"627_CR55","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1108\/ARLA-02-2015-0039","volume":"29","author":"G Rivera","year":"2016","unstructured":"Rivera G, Cox AM. An actor-network theory perspective to study the non-adoption of a collaborative technology intended to support online community participation. Acad Rev Latinoam Adm. 2016;29(3):347\u201365. https:\/\/doi.org\/10.1108\/ARLA-02-2015-0039.","journal-title":"Acad Rev Latinoam Adm"},{"key":"627_CR56","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S140063","author":"G Dranitsaris","year":"2017","unstructured":"Dranitsaris G, Jacobs I, Kirchhoff C, Popovian R, Shane LG. Drug tendering: drug supply and shortage implications for the uptake of biosimilars. Clinicoecon Outcomes Res. 2017. https:\/\/doi.org\/10.2147\/CEOR.S140063.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"3","key":"627_CR57","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/23322373.2022.2071577","volume":"8","author":"L Corsini","year":"2022","unstructured":"Corsini L. The making of a makerspace in Ethiopia: a study of legitimacy using Actor-Network Theory. Afr J Manag. 2022;8(3):399\u2013424. https:\/\/doi.org\/10.1080\/23322373.2022.2071577.","journal-title":"Afr J Manag"},{"issue":"6","key":"627_CR58","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1093\/ecco-jcc\/jjw216","volume":"11","author":"V Razanskaite","year":"2017","unstructured":"Razanskaite V, Bettey M, Downey L, Wright J, Callaghan J, Rush M, et al. Biosimilar infliximab in inflammatory bowel disease: outcomes of a managed switching programme. J Crohns Colitis. 2017;11(6):690\u20136. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjw216.","journal-title":"J Crohns Colitis"},{"key":"627_CR59","unstructured":"O'Connell B, Ciccotosto S, De Lange P. Understanding the application of actor-network theory in the process of accounting change; 2014."},{"issue":"1","key":"627_CR60","doi-asserted-by":"publisher","first-page":"102","DOI":"10.18553\/jmcp.2019.25.1.102","volume":"25","author":"E Leonard","year":"2019","unstructured":"Leonard E, Wascovich M, Oskouei S, Gurz P, Carpenter D. Factors affecting health care provider knowledge and acceptance of biosimilar medicines: a systematic review. J Manag Care Spec Pharm. 2019;25(1):102\u201312. https:\/\/doi.org\/10.18553\/jmcp.2019.25.1.102.","journal-title":"J Manag Care Spec Pharm"},{"issue":"9","key":"627_CR61","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1002\/acr.24012","volume":"72","author":"C Gasteiger","year":"2020","unstructured":"Gasteiger C, Jones AS, Kleinst\u00e4uber M, Lobo M, Horne R, Dalbeth N, et al. Effects of message framing on patients\u2019 perceptions and willingness to change to a biosimilar in a hypothetical drug switch. Arthritis Care Res. 2020;72(9):1323\u201330. https:\/\/doi.org\/10.1002\/acr.24012.","journal-title":"Arthritis Care Res"},{"key":"627_CR62","unstructured":"Generic and Biosimilar Medicines Association. GBMA Education. 2018. Available from: https:\/\/www.gbma.com.au\/gbma-education\/#:~:text=The%20Government%20is%20continuing%20its,for%20completion%20by%20December%202020. [Cited 1 April 2026]."},{"key":"627_CR63","unstructured":"Generic and Biosimilar Medicines Association (GBMA). Government extends the GBMA Education biosimilar education campaign. 2021. Available from: https:\/\/gbma.com.au\/government-extends-the-gbma-education-biosimilar-education-campaign\/. [Cited 18 April 2026]."},{"key":"627_CR64","doi-asserted-by":"publisher","unstructured":"Quinlivan A, Lester S, Barrett C, Whittle S, Rowett D, Black R, et al. Attitudes of australians with inflammatory arthritis to biologic therapy and biosimilars. Rheumatol Adv Pract. 2022; 6(3): rkac099. https:\/\/doi.org\/10.1093\/rap\/rkac099.","DOI":"10.1093\/rap\/rkac099"},{"key":"627_CR65","doi-asserted-by":"publisher","unstructured":"Niaz MS, Suhail S, Mahmood U. Awareness and knowledge of biosimilars among rheumatologists and patients. J Health Rehab Res. 2025; 5(1): 1\u20137. https:\/\/doi.org\/10.61919\/jhrr.v5i1.1755.","DOI":"10.61919\/jhrr.v5i1.1755"},{"key":"627_CR66","unstructured":"Campanelli G. Feeling evergreen: a case study of humira\u2019s patent extension strategies and retroactive assessment of second-line patent validity. Harvard University; 2022."},{"key":"627_CR67","unstructured":"Biosimilars Council. Misinformation on biosimilars costs billions, harms patients, and sows unnecessary doubt around FDA-approved products. 2024. Available from: https:\/\/biosimilarscouncil.org\/resource\/misinformation-biosimilars-costs-billions-harms-patients-sows-unnecessary-doubt-fda-approved-products\/. [Cited 2 June 2026]."}],"container-title":["Pharmaceutical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-026-00627-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40290-026-00627-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-026-00627-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:47:29Z","timestamp":1791449249000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40290-026-00627-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":67,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["627"],"URL":"https:\/\/doi.org\/10.1007\/s40290-026-00627-9","relation":{},"ISSN":["1178-2595","1179-1993"],"issn-type":[{"value":"1178-2595","type":"print"},{"value":"1179-1993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"20 July 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Author Chad Rieger is a PhD candidate in the Faculty of Medicine at the University of Queensland in Brisbane, Australia. He is also the Head of Medical Affairs and Policy with Sandoz Pty Ltd. Australia & New Zealand. Appropriate disclosures on his work with Sandoz Pty Ltd. have been made to ensure no interference with his academic work. No support or funding was provided for this work by Sandoz Pty Ltd, nor from any other party.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No datasets were generated for this review article. Data discussed in this article can be found in the referenced original studies.","order":2,"name":"Ethics","label":"Availability of data and materials","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Chad Rieger: Primary author, completion of search of databases and screening of articles, data extraction, preparation of final manuscript, editing and final review of manuscript. Lisa Hall: Senior author, support of preparation of final manuscript, editing and final review of manuscript. Judith A. Dean: Support of preparation of final manuscript, editing and final review of manuscript. Gregory Merlo: Support of preparation of final manuscript, editing and final review of manuscript. All authors read and approved the final manuscript.","order":7,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}